SGMO Sangamo Therapeutics, Inc.

-0.35  -4%
Previous Close 8.15
Open 8.25
Price To book 4.65
Market Cap 561.12M
Shares 71,939,000
Volume 1,250,989
Short Ratio 10.12
Av. Daily Volume 1,250,230

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiated early 2017 with data due late 2017 or early 2018.
MPS Type 1
Phase 1/2 data due late 2017 or early 2018.
Hemophilia B
Phase 1/2 trial initiated early 2017 with data due late 2017 or early 2018.
MPS Type 2
Data presented Dec 2015
Data presented Dec 2015

Latest News

  1. ETFs with exposure to Sangamo Therapeutics, Inc. : May 25, 2017
  2. Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
  3. Will Sangamo Therapeutics (SGMO) Continue to Surge Higher?
  4. Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status
  5. Edited Transcript of SGMO earnings conference call or presentation 10-May-17 9:00pm GMT
  6. Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy
  7. Sangamo Therapeutics Recognizes International MPS Awareness Day And Celebrates The MPS I And MPS II Communities With Stories Of Hope
  8. Is the Options Market Predicting a Spike in Sangamo Therapeutics (SGMO) Stock?
  9. Sangamo Therapeutics Presents Recent Developments from Research and Clinical Programs at Annual Meeting of the American Society of Gene & Cell Therapy
  10. Why Sangamo Therapeutics Inc. Jumped Higher Today
  11. Today's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Sangamo Therapeutics
  12. Sangamo Therapeutics, Inc. – Value Analysis (NASDAQ:SGMO) : May 11, 2017
  13. Here's Why Sangamo Therapeutics Rocketed Up to 56.3% Higher Today
  14. Why Sangamo Therapeutics Is Surging
  15. Sangamo shares jump on Pfizer collaboration, quarterly results
  16. Sangamo reports 1Q loss
  17. Sangamo Therapeutics Reports First Quarter 2017 Financial Results
  18. Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy
  19. Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SGMO-US : May 9, 2017
  20. Blog Coverage: Sangamo Receives Special Regulatory Designation from FDA for Three of Its Program